ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dostarlimab

Also written as “Dostarlimab”, “TSR-042” and “Dostarlimab (TSR-042)”.

Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 2 companies.

Drug pageDostarlimab: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 20, 202526 company-led studies, 17 open or runningNext primary completion: Nov 23, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only2517 open or runningphase 4since Mar 20, 2025Mar 9, 2016Nov 23, 2026phase 2 · NCT06567782
AGO Research10 open or runningphase 2since Oct 18, 2021Oct 18, 2021none ahead

Also a collaborator on its studies: iTeos Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AGO Research only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named dostarlimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, TSR-042
  2. Oct 18, 2021First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT05126342

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study AGO Research leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05126342Ovarian Neoplasms2WithdrawnNov 1, 20240

How it is read

Names in the registry

  • “Dostarlimab”, 22 entries
  • “TSR-042”, 2 entries
  • “Dostarlimab (TSR-042)”, 1 entry
  • “TSR-042 (Dostarlimab)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.